 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C20H28N4O2 |
| Molar mass | 356.470 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
AB-CHMINACA is anindazole-basedsynthetic cannabinoid. It is a potentagonist of theCB1 receptor (Ki = 0.78 nM) andCB2 receptor (Ki = 0.45 nM) and fully substitutes forΔ9-THC in rat discrimination studies, while being 16x more potent.[3][4] Continuing the trend seen in other cannabinoids of this generation, such asAB-FUBINACA andAB-PINACA, it contains avaline amino acid amide residue as part of its structure, where older cannabinoids contained anaphthyl oradamantane residue.
There have been a number of reported cases of seizures, deaths, and psychotic episodes in relation to this synthetic cannabinoid.[5][6][7][8][9][10][11]
In 2015, AB-CHMINACA became aSchedule I controlled substance in the United States.[12]
AB-CHMINACA is anAnlage II controlled substance in Germany as of May 2015.[13]
As of October 2015 AB-CHMINACA is a controlled substance in China.[14]
AB-CHMINACA is illegal in Switzerland as of December 2015.[15]
AB-CHMINACA is an illegal substance in Russian Federation.
